Conteville

Researchers are investigating bile duct cancers, a rare group of tumors with generally poor outcomes. This study aims to identify markers that can predict how patients respond to treatments like surgery, chemotherapy, targeted therapy, and local treatments, as well as to evaluate the effectiveness and tolerance of these treatments in current practice. The study includes both retrospective and prospective parts, spanning diagnoses from 2003 to 2030, with a focus on improving treatment decisions for patients. The study is a multi-center cohort observing patients diagnosed between 2003 and 2030. It includes those with intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma, excluding ampullomas. Patients are followed for up to 10 years from diagnosis. Data collection involves reviewing treatments such as surgery and chemotherapy, as well as their outcomes and side effects. Past patient data are used for retrospective parts, while new patients diagnosed after 2021 are followed prospectively. Participants will have their medical records reviewed for treatment responses, survival rates, complications, and side effects over a long period. Outcomes measured include overall survival, disease-free survival, progression-free survival, response rates, and postoperative mortality. Genetic studies may also be part of the research with consent. The study allows data use for educational purposes with proper authorization. Participation spans up to 10 years from diagnosis, with follow-up continuing until death or study end.

Researchers are studying serum neurofilament-light chain NfL and Glial Fibrillary Acidic Protein GFAP levels as potential markers to understand the activity and progression of Multiple Sclerosis MS at various stages of the disease. These proteins in the blood may provide insight into disability and disease changes in people living with MS. The study involves collecting blood samples from individuals diagnosed with MS who are part of the OFSEP cohort. These samples will be tested for NfL and GFAP levels at different times, including at the start and over several years, to observe how these markers relate to disease stability or progression. The study will include patients with different disease statuses, including active and stable MS. Participants will provide blood samples periodically and undergo evaluations to track disease activity and progression. Researchers will measure NfL and GFAP levels to compare patients with evolving disease to those with stable conditions over multiple time points, up to six years. The study also monitors disability levels and MRI activity, aiming to better understand MS progression. Participants involvement may last several years depending on follow-up schedules.